The integration allows physicians to order oncology tests and view results directly within their existing clinical workflow.
NeoGenomics announced that its oncology testing portfolio is now available through Epic Aura, enabling access for oncologists and health systems across the US through the Epic electronic health record workflow.
Through this integration, physicians can order what the company describes as a “comprehensive suite of tests,” spanning solid tumors and hematologic malignancies, and view results in the same system they use to manage patient care. This streamlined approach is intended to lower barriers to entry for hospitals and health systems, enhance the scalability of testing capabilities, and could drive a 20-30% increase in test adoption per site, according to a press release from NeoGenomics.
“Clinicians need timely access to the right diagnostics within the systems they already rely on,” says Tony Zook, chief executive officer of NeoGenomics, in a release. “Successfully integrating with Epic enables us to bring our testing capabilities directly into everyday care delivery, with the potential to help patients begin appropriate therapy sooner while allowing health systems to scale precision oncology more efficiently.”
The integration represents a step in the company’s digital health strategy to strengthen connectivity between community oncology practices and large health systems. This infrastructure is designed to support the delivery of next-generation diagnostic capabilities, including liquid biopsy and molecular residual disease.
According to the company, the integration supports faster time to treatment for patients facing a cancer diagnosis by placing diagnostic tools directly into the systems used for everyday care delivery.
ID 435300957 © Aoo3771 | Dreamstime.com
Related Reading:
